Our team is dedicated to addressing the challenging issue of drug resistance in cancer therapy, particularly focusing on two commonly used anticancer agents: trastuzumab (the most widely used biological macromolecular anticancer drug) and gemcitabine (a frequently used small-molecule anticancer drug). Studies have revealed that both trastuzumab-resistant tumor cells and gemcitabine-resistant pancreatic cancer cells exhibit concurrent expression of CD47 and HER2 targets, forming a dual barrier of "immune escape – proliferation signaling".

In response, we have innovatively developed a CD47/HER2 bispecific antibody, named NanosphinX, which simultaneously blocks both targets. On one hand, it inhibits the HER2 signaling pathway to directly suppress tumor proliferation; on the other hand, it reverses CD47-mediated immune suppression, significantly enhancing macrophage-mediated antibody-dependent cellular phagocytosis (ADCP). This approach results in marked inhibition of tumor growth in vivo while effectively overcoming chemotherapy-induced angiogenesis and immunosuppression.